litlas
Log inCreate account

D. Ross Camidge

Active 1999–2025

Also published as
D Ross Camidge
220
Papers
58,463
Citations
112
h-index
213
i10-index

Citations

Citations per year for D. Ross Camidge1993: 1 citations1994: 2 citations1997: 1 citations1999: 3 citations2000: 7 citations2001: 14 citations2002: 9 citations2003: 6 citations2004: 11 citations2005: 9 citations2006: 8 citations2007: 7 citations2008: 15 citations2009: 21 citations2010: 69 citations2011: 219 citations2012: 387 citations2013: 493 citations2014: 564 citations2015: 766 citations2016: 745 citations2017: 740 citations2018: 814 citations2019: 2,302 citations2020: 2,683 citations2021: 2,664 citations2022: 2,107 citations2023: 1,598 citations2024: 2,315 citations2025: 1,142 citations2026: 35 citations1995–1996: no citations, so these years are not shown1998: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,775 citing papers, 25.1% of this breakdownChina: 2,595 citing papers, 13.6% of this breakdownItaly: 1,079 citing papers, 5.7% of this breakdownUnited Kingdom: 905 citing papers, 4.8% of this breakdownGermany: 836 citing papers, 4.4% of this breakdownFrance: 829 citing papers, 4.4% of this breakdownJapan: 807 citing papers, 4.2% of this breakdownSpain: 701 citing papers, 3.7% of this breakdownCanada: 638 citing papers, 3.4% of this breakdownSouth Korea: 593 citing papers, 3.1% of this breakdownNetherlands: 532 citing papers, 2.8% of this breakdownSwitzerland: 529 citing papers, 2.8% of this breakdown
0%25.1%Other 22%

Institutions

Fields

  • Medicine70.1%
  • Biochemistry, Genetics and Molecular Biology23.2%
  • Immunology and Microbiology2.1%
  • Computer Science0.8%
  • Chemistry0.6%
  • Engineering0.6%
  • Other2.6%

Topics

  • Lung Cancer Treatments and Mutations14.3%
  • Lung Cancer Research Studies7.3%
  • Cancer Genomics and Diagnostics5.2%
  • Cancer Immunotherapy and Biomarkers4.9%
  • Lung Cancer Diagnosis and Treatment4.6%
  • Brain Metastases and Treatment2.6%
  • Other61.1%

Coauthors

All papers

Open in search
  1. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    Authors: J. Mazieres, Alexander Drilon, Amélie Lusque, Laurent Mhanna, Alexis B. Cortot, Laura Mezquita, Alesha A. Thai, Céline Mascaux, S. Couraud, Rémi Veillon, Michel M. van den Heuvel, Joel W. Neal, Nir Peled, Martin Früh, Terry L. Ng, V. Gounant, Sanjay Popat, Joachim Diebold, Joshua K. Sabari, Viola W. Zhu, Sacha I. Rothschild, Paolo Bironzo, Alex Martínez‐Martí, Alessandra Curioni‐Fontecedro, Rafael Rosell, Mickaël Lattuca-Truc, Marcel Wiesweg, Benjamin Besse, Benjamin Solomon, Fabrice Barlési, Robert D. Schouten, Heather A. Wakelee, D. Ross Camidge, Gérard Zalcman, Silvia Novello, Sai‐Hong Ignatius Ou, Julie Milia, Oliver Gautschi - Annals of Oncology 2019 cited by 1,361

  2. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

    Authors: Solange Peters, D. Ross Camidge, Alice T. Shaw, Shirish M. Gadgeel, Jin Seok Ahn, Dong‐Wan Kim, Sai‐Hong Ignatius Ou, M. Pérol, Rafał Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noé, Peter N. Morcos, Tony Mok - New England Journal of Medicine 2017 cited by 2,455

  3. Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer

    Authors: D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, James Chih‐Hsin Yang, Ji‐Youn Han, Jong Seok Lee, Maximilian J. Hochmair, Jacky Yu-Chung Li, Gee‐Chen Chang, Ki Hyeong Lee, Cesare Gridelli, Angelo Delmonte, Rosario García Campelo, Dong‐Wan Kim, Alessandra Bearz, Frank Griesinger, Alessandro Morabito, Enriqueta Felip, Raffaele Califano, Sharmistha Ghosh, Alexander I. Spira, Scott Gettinger, Marcello Tiseo, Neeraj Gupta, J. Haney, David Kerstein, Sanjay Popat - New England Journal of Medicine 2018 cited by 976

  4. Response assessment criteria for brain metastases: proposal from the RANO group

    Authors: Nancy U. Lin, Eudocia Q. Lee, Hidefumi Aoyama, Igor J. Barani, Daniel P. Barboriak, Brigitta G. Baumert, Martin Bendszus, Paul D. Brown, D. Ross Camidge, Susan M. Chang, Janet Dancey, Elisabeth G.E. de Vries, Laurie E. Gaspar, Gordon J. Harris, F. Stephen Hodi, Steven N. Kalkanis, Mark E. Linskey, David Macdonald, Kim Margolin, Minesh P. Mehta, David Schiff, Riccardo Soffietti, John H. Suh, Martin J. van den Bent, Michael A. Vogelbaum, Patrick Y. Wen - The Lancet Oncology 2015 cited by 1,088

  5. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study

    Authors: Daniel R. Gomez, Chad Tang, Jianjun Zhang, George R. Blumenschein, Mike Hernández, J. Jack Lee, Rong Ye, David A. Palma, Alexander V. Louie, D. Ross Camidge, Robert C. Doebele, Ferdinandos Skoulidis, Laurie E. Gaspar, James W. Welsh, Don L. Gibbons, José A. Karam, Brian D. Kavanagh, Anne S. Tsao, Boris Sepesi, Stephen G. Swisher, John V. Heymach - Journal of Clinical Oncology 2019 cited by 1,270

  6. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

    Authors: Tony Mok, D. Ross Camidge, Shirish M. Gadgeel, Rafael Rosell, Rafał Dziadziuszko, D.-W. Kim, M. Pérol, S.-H.I. Ou, Jin Seok Ahn, A. Shaw, Walter Bordogna, Vlatka Smoljanović, Magalie Hilton, Thorsten Ruf, Johannes Noé, Solange Peters - Annals of Oncology 2020 cited by 686

  7. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer

    Authors: Roy S. Herbst, Margarita Majem, Fabrice Barlesi, Enric Carcereny, Quincy Chu, Isabelle Monnet, Alfredo Sanchez-Hernandez, Shaker Dakhil, D. Ross Camidge, Leanne Winzer, Yee Soo-Hoo, Zachary A. Cooper, Rakesh Kumar, John Bothos, Charu Aggarwal, Alex Martinez-Marti - Journal of Clinical Oncology 2022 cited by 287

  8. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Authors: Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang, D. Ross Camidge, Benjamin Solomon, Ravi Salgia, Gregory J. Riely, Marileila Varella‐Garcia, Geoffrey I. Shapiro, Daniel B. Costa, Robert C. Doebele, Long P. Le, Zongli Zheng, Weiwei Tan, Patricia Stephenson, S. Martin Shreeve, L. Tye, James G. Christensen, Keith D. Wilner, Jeffrey W. Clark, A. John Iafrate - New England Journal of Medicine 2014 cited by 1,993

  9. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Authors: Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, David J. Kwiatkowski, A. John Iafrate, Ignacio I. Wistuba, Marileila Varella‐Garcia, Wilbur A. Franklin, Samuel L. Aronson, Pei-Fang Su, Yu Shyr, D. Ross Camidge, Lecia V. Sequist, Bonnie S. Glisson, Fadlo R. Khuri, Edward B. Garon, William Pao, Charles M. Rudin, Joan H. Schiller, Eric B. Haura, Mark A. Socinski, Keisuke Shirai, Heidi Chen, Giuseppe Giaccone, Marc Ladanyi, Kelly Kugler, John D. Minna, Paul A. Bunn - JAMA 2014 cited by 1,744

  10. Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

    Authors: Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne - New England Journal of Medicine 2013 cited by 3,406

  11. Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

    Authors: D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, James Chih‐Hsin Yang, Ji‐Youn Han, Maximilian J. Hochmair, Ki Hyeong Lee, Angelo Delmonte, M.R. García Campelo, Dong‐Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander I. Spira, Scott Gettinger, Marcello Tiseo, Huamao Mark Lin, Yuyin Liu, Florin Vranceanu, Huifeng Niu, Pingkuan Zhang, Sanjay Popat - Journal of Thoracic Oncology 2021 cited by 372

  12. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

    Authors: Alexander Drilon, Sai‐Hong Ignatius Ou, Byoung Chul Cho, Dong‐Wan Kim, Jeeyun Lee, Jessica J. Lin, Viola W. Zhu, Myung‐Ju Ahn, D. Ross Camidge, Judy Nguyen, Dayong Zhai, Wei Deng, Zhongdong Huang, Evan Rogers, Juliet Liu, Jeff Whitten, John K. C. Lim, Shanna Stopatschinskaja, David M. Hyman, Robert C. Doebele, J. Jean Cui, Alice T. Shaw - Cancer Discovery 2018 cited by 480

  13. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

    Authors: Benjamin Solomon, Benjamin Besse, Todd M. Bauer, Enriqueta Felip, Ross A. Soo, D. Ross Camidge, Rita Chiari, Alessandra Bearz, Chia‐Chi Lin, Shirish M. Gadgeel, Gregory J. Riely, Eng Huat Tan, Takashi Seto, Leonard P. James, Jill S. Clancy, Antonello Abbattista, Jean-François Martini, Joseph Chen, Gerson Peltz, Holger Thurm, Sai‐Hong Ignatius Ou, Alice T. Shaw - The Lancet Oncology 2018 cited by 789

  14. Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

    Authors: Alexander Drilon, D. Ross Camidge, W. Marston Linehan, Sang‐We Kim, Benjamin Solomon, Rafał Dziadziuszko, Benjamin Besse, Kōichi Goto, Adrianus J. de Langen, Jürgen Wolf, Ki Hyeong Lee, Sanjay Popat, Christoph Springfeld, Misako Nagasaka, Enriqueta Felip, Nong Yang, Vamsidhar Velcheti, Shun Lü, Steven Kao, Christophe Dooms, Matthew Krebs, Wenxiu Yao, Muhammad Shaalan Beg, Xiufeng Hu, Denis Moro‐Sibilot, Parneet Cheema, Shanna Stopatschinskaja, Minal Mehta, Denise Trone, Armin Graber, Gregory E. Sims, Yong Yuan, Byoung Chul Cho - New England Journal of Medicine 2024 cited by 210

  15. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

    Authors: Daniel R. Gomez, George R. Blumenschein, J Jack Lee, Mike Hernández, Rong Ye, D. Ross Camidge, Robert C. Doebele, Ferdinandos Skoulidis, Laurie E. Gaspar, Don L. Gibbons, José A. Karam, Brian D. Kavanagh, Chad Tang, Ritsuko Komaki, Alexander V. Louie, David A. Palma, Anne S. Tsao, Boris Sepesi, William N. William, Jianjun Zhang, Qiuling Shi, Xin Shelley Wang, Stephen G. Swisher, John V. Heymach - The Lancet Oncology 2016 cited by 1,086

  16. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

    Authors: Charles A. Powell, Shanu Modi, Hiroji Iwata, Shunji Takahashi, Egbert F. Smit, Salvatore Siena, D.-Y. Chang, E. Macpherson, A. Qin, Jasmeet Singh, Corina Taitt, Norah J. Shire, D. Ross Camidge - ESMO Open 2022 cited by 231

  17. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

    Authors: D. Ross Camidge, Robert C. Doebele, Keith M. Kerr - Nature Reviews Clinical Oncology 2019 cited by 559

  18. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

    Authors: D. Ross Camidge, Fabrice Barlési, Jonathan W. Goldman, Daniel Morgensztern, Rebecca S. Heist, Everett E. Vokes, Alexander I. Spira, Eric Angevin, Wu‐Chou Su, David S. Hong, John H. Strickler, Monica Motwani, Martin Dunbar, Apurvasena Parikh, Elysa Noon, Vincent Blot, Jun Wu, Karen Kelly - Journal of Clinical Oncology 2022 cited by 104

  19. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

    Authors: Alexander Drilon, Jeffrey W. Clark, Jared Weiss, Sai‐Hong Ignatius Ou, D. Ross Camidge, Benjamin Solomon, Gregory A. Otterson, Liza C. Villaruz, Gregory J. Riely, Rebecca S. Heist, Mark M. Awad, Geoffrey I. Shapiro, Miyako Satouchi, Toyoaki Hida, Hidetoshi Hayashi, Danielle Murphy, Sherry Wang, Sherry Li, Tiziana Usari, Keith D. Wilner, Paul K. Paik - Nature Medicine 2020 cited by 393

  20. Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions

    Authors: Ayal A. Aizer, Nayan Lamba, Manmeet S. Ahluwalia, Kenneth Aldape, Adrienne Boire, Priscilla K. Brastianos, Paul D. Brown, D. Ross Camidge, Veronica Chiang, Michael A. Davies, Leland Hu, Raymond Y. Huang, Timothy J. Kaufmann, Priya Kumthekar, Keng Lam, Eudocia Q. Lee, Nancy U. Lin, Minesh P. Mehta, Michael Parsons, David A. Reardon, Jason P. Sheehan, Riccardo Soffietti, Hussein A. Tawbi, Michael Weller, Patrick Y. Wen - Neuro-Oncology 2022 cited by 192

  21. Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer

    Authors: Sha Zhao, Shengxiang Ren, Tao Jiang, Bo Zhu, Xuefei Li, Chao Zhao, Yijun Jia, Jinpeng Shi, Limin Zhang, Xiaozhen Liu, Meng Qiao, Xiaoxia Chen, Chunxia Su, Hui Yu, Caicun Zhou, Jun Zhang, D. Ross Camidge, Fred R. Hirsch - Cancer Immunology Research 2019 cited by 334

  22. Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

    Authors: Neal Ready, Patrick A. Ott, Matthew D. Hellmann, Jon Zugazagoitia, Christine L. Hann, Filippo de Braud, Scott Antonia, Paolo A. Ascierto, Víctor Moreno, Akin Atmaca, Stefania Salvagni, Matthew H. Taylor, Asim Amin, D. Ross Camidge, Leora Horn, Emiliano Calvo, Ang Li, Wen Lin, Margaret K. Callahan, David R. Spigel - Journal of Thoracic Oncology 2019 cited by 325

  23. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Authors: Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, Weiwei Tan, Leena Gandhi, Mari Mino–Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate - New England Journal of Medicine 2010 cited by 4,504

  24. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

    Authors: Alice T. Shaw, Benjamin Solomon, Benjamin Besse, Todd M. Bauer, Chia‐Chi Lin, Ross A. Soo, Gregory J. Riely, Sai‐Hong Ignatius Ou, Jill S. Clancy, Sherry Li, Antonello Abbattista, Holger Thurm, Miyako Satouchi, D. Ross Camidge, Steven Kao, Rita Chiari, Shirish M. Gadgeel, Enriqueta Felip, Jean‐François Martini - Journal of Clinical Oncology 2019 cited by 379